FDA to offer faster drug reviews to companies promoting 'national priorities'
WASHINGTON — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting 'the health interests of Americans,' under a new initiative announced Tuesday.
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases . Regular drug reviews take about 10 months.
Since arriving at the FDA in April, Makary has repeatedly told FDA staff they need to 'challenge assumptions' and rethink procedures. In a medical journal commentary published last week, Makary suggested the agency could conduct 'rapid or instant reviews,' pointing to the truncated process used to authorize the first COVID-19 vaccines under Operation Warp Speed.
For the new program, the FDA will issue a limited number of 'national priority vouchers' to companies 'aligned with U.S. national priorities,' the agency said in a statement. The special designation will give the selected companies access to extra FDA communications, streamlined staff reviews and the ability to submit much of their product information in advance.
Speeding up drug approvals has long been a priority of the pharmaceutical industry, which has successfully lobbied Congress to create a variety of special programs and pathways for faster reviews.
Many aspects of the plan announced Tuesday overlap with older programs. But the broad criteria for receiving a voucher will give FDA officials unprecedented discretion in deciding which companies can benefit from the fastest reviews.
'The ultimate goal is to bring more cures and meaningful treatments to the American public,' Makary said in a statement.
Makary previously said the FDA should be willing to ease its scientific requirements for certain drugs, for instance, by not always requiring randomized studies in which patients are tracked over time to track safety and effectiveness. Such trials are generally considered the gold standard of medical research, though the FDA has increasingly been willing to accept smaller, less-definitive studies for rare or life-threatening diseases .
In several recent cases , the FDA has faced criticism for approving drugs based on preliminary data that didn't ultimately show benefits for patients.
The push to rapidly accelerated drug approvals is the opposite approach that Makary and his boss, Health Secretary Robert F. Kennedy Jr. , have taken on vaccines.
Promising a 'return to gold-standard science,' Kennedy previously announced that all new vaccines would have to be compared to placebo, or a dummy shot, to win approval. Kennedy and Makary also have announced a stricter policy on seasonal updates to COVID-19 shots, saying they will have to undergo new testing before they can be approved for use in healthy children and most adults.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
19 minutes ago
- CNET
Experiencing Hair Loss? This First-Ever Prescription Gummy for Hair Regrowth May Be the Solution
Hers, a telehealth company that provides online healthcare services and products for women, announced on Tuesday the launch of its Biotin plus Minoxidil Gummy, the first-of-its-kind prescription gummy formulated to support hair regrowth. Available through this gummy combines prescription-strength minoxidil, the only FDA-approved ingredient for female hair loss, with biotin, a popular vitamin for supporting healthy skin, hair and nails. Minoxidil is clinically proven to regrow thicker, fuller hair in three to six months (based on studies of oral minoxidil up to 2.5 mg per day at various doses). It's the first prescription hair regrowth gummy to hit the market, and it offers women a more convenient way to stay consistent with treatment, something Hers chief medical officer and OB-GYN Dr. Jessica Shepherd says is often overlooked in traditional regimens. "The gummy is a once-daily dose that's designed to help women stick to their prescribed hair regimens as deemed clinically necessary by their provider to address their individual needs," she says. Hers Shepherd told CNET that everything about the product, from the packaging to the vegan formula to the taste (green apple flavor) and texture, was crafted with women's preferences in mind. The goal is a treatment that feels more like a self-care ritual than a chore. Why a gummy? Unlike traditional pills or topicals, the Biotin plus Minoxidil Gummy was formulated with adherence in mind. The proprietary compounded formula allows providers to personalize each prescription to individual needs, including adjusting the dosage to minimize side effects or combining multiple ingredients to tackle various concerns simultaneously. "By leveraging the power of personalization, we're making it possible for women to access treatment designed to address their individual needs for their unique body, lifestyle and goals. This is the benefit of compounding," says Shepherd. How much does it cost, and where can I get it? The Biotin plus Minoxidil Gummy is available through Hers after a virtual consultation with one of its licensed providers. Each prescription is customized based on your unique hair loss patterns and goals. Hers strives to offer patients affordable treatments without insurance (no insurance is accepted), and the gummies start at $35 per month. To learn more or schedule a consultation, visit
Medscape
24 minutes ago
- Medscape
Fast Five Quiz: ATTR-CM Presentation and Diagnosis
Transthyretin amyloid cardiomyopathy (ATTR-CM) presents with a diverse range of symptoms involving the cardiovascular and peripheral systems. The clinical manifestations of ATR-CM are typically related to the location of amyloid fibrils in various tissues. In individuals with hereditary transthyretin amyloid, the type of TTR mutation also influences the presentation. Owing to the heterogeneity of presentation, diagnosis might be delayed for several years after symptom onset. In addition, the true prevalence of the disease is unknown because many cases go undiagnosed and patients are also often misdiagnosed with more common conditions. Are you up to date on your understanding of ATTR-CM presentation and diagnosis? Test your knowledge with a quick quiz. ATTR-CM can affect several organ systems outside of the heart and periphery, disrupting gastrointestinal, genitourinary, auditory, and vision functions. Ocular manifestations (usually caused by vitreous deposits) include conjunctivitis, dry eye, floaters, reduced visual acuity, and eye pain. Regarding other extracardiac manifestations, neuropathic pain, a consequence of deposits in the peripheral nerves, can result in weakness and impaired sensation, as well as autonomic dysfunction that manifests as sexual or urinary dysfunction. Cardiac manifestations of ATTR-CM can include symptoms associated with chronic heart failure, such as dyspnea on exertion and peripheral edema, and arrythmias (such as syncope). Learn more about the clinical presentation of ATTR-CM. Echocardiography can reveal signs of amyloid deposition within the heart. Characteristic imaging findings can include increased ventricular wall thickness, increased septal thickness, valvular thickening, valvular insufficiency, and atrial enlargement. The myocardium might also appear to have a granular "sparkling" appearance, as indicated by bright spots in the image. Although this sign alone is not sufficient to confirm a diagnosis, it is suggestive of ATTR-CM and can help with diagnosis. Thinning of the valvular walls and reduced septal thickness are usually not indicative of cardiac amyloid deposition. Though increased diastolic volume might be seen in patients with cardiac amyloid deposition, this factor alone is not definitive. Specifically, a common presentation of cardiac amyloidosis is ' rapidly progressive diastolic dysfunction in a nondilated ventricle.' Learn more about cardiac imaging in AT TR-CM. Patients who exhibit possible signs of cardiac amyloidosis should be screened using electrophysiology and imaging to detect any abnormalities due to amyloid deposits. If those results are suggestive of cardiac amyloidosis, additional tests must be ordered to determine the amyloidosis type. The first step in the differential diagnostic pathway includes testing for the presence of monoclonal proteins. A serum/kappa lambda free light chain ratio of < 0.26 or > 1.65 or an abnormal serum/urine immunofixation electrophoresis can indicate amyloid light chain amyloidosis, but alone these factors are usually not definitive for ATTR-CM diagnosis. However, absence of monoclonal proteins and grade 2/3 uptake of 99mTc-pyrophosphate highly indicate AT TR-CM; these factors can be used for diagnosis. TTR mutation does not need to be present for ATTR-CM diagnosis and alone does not strongly indicate this disease; rather, genetic testing for TTR mutations should be conducted to distinguish between hereditary and wild-type ATTR-CM following diagnosis. Learn more about conducting a workup for ATTR-CM. Many neurologic symptoms associated with ATTR-CM overlap with those of other conditions, including Charcot-Marie-Tooth disease. Peripheral neuropathy is a common neurologic symptom of ATTR-CM. Other neurologic symptoms can include autonomic dysfunction, gastroparesis, orthostatic hypotension, erectile dysfunction, and urinary incontinence. As such, ATTR-CM might also be misdiagnosed as other hereditary motor and sensory neuropathies, such as Refsum disease. Therefore, these conditions should be included in a differential diagnosis in patients presenting with neurologic symptoms. Though some with ATTR-CM might experience seizures (usually in cases of patients with leptomeningeal amyloidosis), they are not common. Muscle weakness usually occurs distally in patients with ATTR-CM. Sudden onset of sensory impairment is less common in patients with ATTR-CM and is more characteristic of transthyretin amyloid polyneuropathy. Learn more about performing a differential diagnosis of ATTR-CM. Subcutaneous fat aspiration, which is most commonly used for tissue biopsy, can be sufficient for amyloid detection. While biopsy of samples from organs directly involved in ATTR-CM can be advantageous because sensitivity is reportedly higher, subcutaneous fat aspiration is a less invasive method that can be helpful in diagnosis. However, if tissue biopsy is negative in a patient with a high clinical suspicion of ATTR-CM, or if cardiac scintigraphy is unavailable or negative, endomyocardial biopsy should be performed. It is often used to confirm ATTR-CM diagnosis, along with other forms of cardiac amyloidosis. Learn more about approach considerations for ATTR-CM evaluation.
Chicago Tribune
26 minutes ago
- Chicago Tribune
Chicago-based Kraft Heinz pulling artificial dyes from its US products in 2027
Chicago's Kraft Heinz will be pulling artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products with the dyes. The move comes nearly two months after U.S. health officials said that they would urge foodmakers to phase out petroleum-based artificial colors in the nation's food supply. Kraft Heinz said Tuesday that almost 90% of its U.S. products already don't contain food, drug & cosmetic colors, but that the products that do still use the dyes will have them removed by the end of 2027. FD&C colors are synthetic additives that are approved by the U.S. Food and Drug Administration for use in food, drugs and cosmetics. Kraft Heinz said that many of its U.S. products that still use the FD&C colors are in its beverage and desserts categories, including certain products sold under brands including Crystal Light, Kool Aid, Jell-O and Jet Puffed. The company said that it will instead use natural colors for the products. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio,' Pedro Navio, North America President at Kraft Heinz, said in a statement. Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup. The company plans to work with licensees of its brands to encourage them to remove the dyes. In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats. Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods. Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
